Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Acquired Immunodeficiency Syndrome (AIDS) Market In The Coming Years?

The market size for acquired immunodeficiency syndrome (AIDS) has experienced substantial growth in the recent past. It is predicted to escalate from $32.09 billion in 2024 to a value of $33.75 billion in 2025, marking a compound annual growth rate (CAGR) of 5.2%. Contributing to the growth during the historic period has been factors such as increased rates of HIV infection, heightened government funding towards HIV treatment, the proliferation of global awareness programs, refinements in diagnostic technology, as well as burgeoning support from non-governmental bodies.

The market size for Acquired Immunodeficiency Syndrome (AIDS) is forecasted to enjoy a substantial uptick in the forthcoming years, escalating to $41.28 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 5.2%. The anticipated rise in this period is linked to the augmenting demand for prolonged-duration injectable therapies, increased adoption of pre-exposure prophylaxis (PrEP), swelling investments in HIV cure research, growth of telemedical services for HIV care, an upswing in the focus on personalized medicine, and ballooning awareness regarding early HIV detection. Significant trends in the projected period consist of moving towards single-tablet regimens, a growing predilection for injectable and implantable HIV therapies, a surge in the requirement for digital health solutions in managing HIV, a budding interest in practical HIV cure methodologies, and an enlarging influence of artificial intelligence in pharmaceutical discovery.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

The escalating incidence of HIV is forecasted to spur the development of the Acquired Immunodeficiency Syndrome (AIDS) market in the future. The term HIV infection is used to describe the ailment resulting from the Human Immunodeficiency Virus (HIV), a disease that attacks the immune system, compromising its ability to defend against infections and other maladies. This surge in HIV infection rates results from exposure to unprotected sex with an infected individual, using shared needles or syringes, obtaining contaminated blood, engaging in sexual activities with multiple partners, having a weakened immune system, or having prior sexually transmitted infections. AIDS management benefits those coping with HIV by encouraging early detection, broadening the reach of potent antiretroviral therapies, heightening preventative methods, and fortifying health care systems, which ultimately leads to improved control over the virus’s proliferation. In one illustration, data from the European Centre for Disease Prevention and Control (ECDC), a Sweden-based agency of the European Union, stated in November 2024 that 112,883 HIV diagnoses had been made across 47 of the 53 countries in the region in 2023, with 24,731 cases documented in the European Union/European Economic Area (EU/EEA). HIV diagnoses overall had a crude rate of 12.7 per 100,000 population, a 2.4% increase from the 12.4 per 100,000 rate observed in the previous year, 2022. Consequently, the rise in HIV infections is propelling the growth of the Acquired Immunodeficiency Syndrome (AIDS) market.

Which Sub-Segments Are Driving Growth Within The Acquired Immunodeficiency Syndrome (AIDS) Market?

The acquired immunodeficiency syndrome (aids)market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral; Parenteral

4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications

5) By Distribution Channel: Offline; Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections

What Current And Upcoming Trends Are Shaping The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading firms in the acquired immunodeficiency syndrome (AIDS) market are concentrating on creating innovative treatments like long-lasting injectables, which enhanced patient adherence, decrease dosing frequency, and provide a more expedient substitute for daily oral antiretroviral treatments. Long-lasting injectables are drugs dispensed through an injection designed to gradually dispense their active components over a longer period, enabling less frequent dosage compared to traditional oral treatments. For example, in January 2025, GSK plc., a British pharmaceutical firm, gained approval from the European Commission for its long-lasting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is approved for adolescents aged 12 and above living with HIV and is dispensed via intramuscular injection, usually every one or two months, subject to the specific treatment schedule. The extended nature of these injections could enhance adherence levels among teenagers who find daily pill routines challenging.

Which Players Are Shaping The Competitive Landscape Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

How Do Regional Dynamics Influence The Acquired Immunodeficiency Syndrome (AIDS) Market Performance?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2025, By The Business Research Company

Hiv Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Immune Health Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immune-health-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model